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Summary 
An animal modal has been used to address the question of the biological importance of the known 
structural difference between the two isotypes of human C4, i.e.,  C4A and C4B. Guinea pigs 
deficient in  C4 were reconstituted  transiently  with  either  human  C4A  or  C4B protein  and 
immunized with the bacteriophage qbX174. Resttlts from this study showed that C4A-reconstituted 
animals made a secondary response, i.e., switch from IgM to IgG; whereas the C4B-reconstituted 
animals  did not. 
M 
HC class I and class II proteins are highly polymorphic 
so as to increase the efficiency of binding to a wide 
range of peptides for antigen presentation (1-3). Of the class 
III proteins in humans,  the fourth component  of comple- 
ment (C4) is also highly polymorphic, and >35 allotypes have 
been recognized (4-6).  Null alleles of C4 are also common 
with a frequency of 0.1-0.3 in various populations as the re- 
sult of gene deletions, gene conversions, and silent mutations 
(7-10).  Comparison of the derived amino acid sequence of 
two common alleles of the C4A and C4B loci indicates that 
they are nearly identical with only 11 base substitutions, of 
which 10 are clustered within a small region of the ot chain 
of C4, namely C4d (11, 12).  Of these 10 base changes,  six 
appear to be isotypic and the remaining  allotypic based on 
serological determinants. 
Porter (13) proposed that  the polymorphism of C4 was 
important  in binding  to a wide range of antigens or anti- 
bodies. In a primary response, recognition of antigen by nat- 
ural antibody is amplified by activation of the classical pathway 
of complement (14). An early step in this pathway is cleavage 
of C4 to C4b by the proteinase activity of C1. This exposes 
a highly reactive internal  thioester, which is readily hydro- 
lyzed by water unless a suitable acceptor is available;  a cova- 
lent bond (either amide or ester) is then formed via a trans- 
acylation reaction (15). The efficiency of binding depends on 
the allotype of C4 and the chemical nature of the antigen 
or antibody. In general, allotypes of C4A bind preferentially 
to free amino groups of proteins, whereas those of C4B form 
ester bonds with carbohydrate or side chains of hydroxyl- 
containing amino acids,  i.e.,  Set, Thr,  or Tyr (16,  17). This 
apparent selectivity appears to be the result of electrostatic 
and steric interactions between the isotypic region (residues 
1101-1106)  in the c~ chain of C4 and the acceptor molecule 
as shown by site-directed mutagenesis  (18). 
To determine if the selectivity of the two isotypes would 
affect the biological function, C4-defident guinea pigs (C4Def 
g.p.'s) 1 were  reconstituted  transiently  with  either  human 
C4A or C4B protein  and immunized  with bacteriophage 
~bX174. Results from this study show that transient recon- 
stitution  with  C4A but not C4B induced a secondary re- 
sponse characterized by IgM to IgG switching. 
Materials and Methods 
Plaque and Neutralization Assays.  The neutralization  assay de- 
scribed by Ochs et al. (19) was performed. In general, serum was 
diluted by 10 x  serial dilutions  in phage buffer, and 100/~1 was 
added to an equal volume of phage (150 PFU) and incubated at 
37~  for 60 rain. As a control,  test dilution is plated immediately 
after adding phage and Escherichia coil Subsequently, test sera and 
phage are added to E. coli in soft agar and plated. PFU are counted 
after a 3-h incubation at 37~  Results are evaluated by a reciprocal 
of the dilution required to neutralize 50% of PFU. IgM and IgG 
were distinguished based on the sensitivity of the former to mer- 
captoethanol.  Test sera are incubated overnight in 0.1 M mercap- 
toethanol  before assay. 
Immunization Protocol.  Male  C4 Def/N g.p:s (inbred strain origi- 
nated from a National Institutes of Health colony) of'~750 g were 
used for this study. MHC-matched strain 13 g.p:s (obtained from 
NIH) of equivalent weight were used as normal controls. For nega- 
Abbreviation used in this paper: C4Def g.p., C4-deficient guinea pig. 
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Volume 175  February 1992  537-543 tive serum control, C4 Def/N g.p's were bled before immuniza- 
tion. g.p.'s were injected (intracardiac)  with a dose of 2  ￿  109 
PFU/kg for both the primary and secondary (4 wk later) immuni- 
zations. For transient reconstitution, antigen was mixed with 2.5 
mg of human C4A or C4B in I ml of sterile PBS or 3 ml of normal 
g.p.  serum (strain  13) before injection. Approximately 0.5 ml of 
blood was taken within 30 min of injection via puncture of the 
retro-orbital sinus  to test for circulating phage and C4 activity. 
Purification of  Human Complement  C4.  Human C4 was purified 
by using a two-step procedure of affinity chromatography (mAb 
specific for C4 B chain was a gift from Dr. Paul Levine, Washington 
University School of Medicine,  St. Louis, MO) and fractionation 
of inactive from active C4 by FPLC mono-Q as described by Dodds 
and Law (20). The separate isotypes were purified from plasma of 
individuals  typed as deficient in either C4A or C4B. The affinity 
columns were prepared by coupling protein A-purified antibody 
to affi-ge110 (Big-Red Laboratories, Richmond, CA) using manufac- 
turer's protocol. C4 was eluted at high pH (pH 10.5) as described 
(20). Eluted fractions were directly fractionated on a 1-ml mono-Q 
column (Pharmacia Fine Chemicals,  Piscataway, NJ) using a FPLC 
apparatus and active C4 eluted using a gradient of 0.1-0.5 M NaC1 
in 20 mM Tris/C1, pH 7.2. Pooled C4 was assayed for hemolytic 
activity, and aliquots were stored at  -80~  The relative amounts 
of active C4, i.e., 2.5 mg, were determined by calculating Z U/m1 
(1 Z  U  =  -In [1  -  fractional lysis]) for each isotype and com- 
paring with a standard plasma  sample  of C4A/C4B.  Since C4B 
is about fourfold more active in this assay than C4A, the number 
of units was corrected for the difference. Thus, an equivalent number 
of units of C4A and C4B could be determined. As an independent 
assay, the purified C4 was treated with Cls, and the products were 
analyzed on SDS-PAGE gels. The level of activity could be deter- 
mined as inactive C4 ~  chain is insensitive  to cleavage with Cls 
as described (18). The hemolytic assay used was the same described 
previously (18). 
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Figure 1.  Comparison  of human C4A and C4B with g.p. C4 protein 
for decay  in hemolytic activity in vivo. C4-deficient  g.p. were injected in- 
travenously with either 2.5 mg of purified active human C4A or C4B 
or with 3 ml of fresh normal g.p. serum as a source of C4. Animals were 
bled at various time intervals and assayed for functional C4 activity. 
was confirmed by analysis of blood samples, which were taken 
within  30 min postimmunization. 
Clearance of the bacteriophage after the primary and sec- 
ondary  immunization  was  followed  by  analyzing  serum 
samples taken at intervals over the first 48 h. After the pri- 
mary immunization,  the phage were cleared to background 
by 48 h at a similar rate for all animals (Fig. 3 a). In contrast, 
a distinct difference in clearance among the groups was ob- 
served after the second immunization 4 wk later (Fig. 3 b). 
The level of circulating phage was <10 PFU/ml in strain 13 
animals  within  the first 0.5  h  of the injection of antigen. 
Comparison of the reconstituted C4Def g.p's at 0.5 h showed 
Results 
Reconstitution of C4Def g.p. with Human C4 Protein.  Pre- 
vious studies have shown that the impaired immune response 
of C4Def g.p's (21) would be restored by injection of 3 ml 
of normal g.p. serum at the time of primary immunization 
(19, 22). An equivalent amount of human C4 was determined 
to be 2.5  mg based on results  from an hemolytic assay in 
vitro (data not shown).  To determine if human C4 would 
be inactivated or cleared at a rate different from g.p. C4, C4Def 
g.p's were reconstituted with 2.5 mg of human C4A, C4B, 
or 3 ml of normal g.p.  serum,  and the level of C4 activity 
was determined over 48 h. The results in Fig.  1 show that 
the two isotypes of human C4 decayed at a similar rate, which 
was similar to that of g.p. C4. The lower hemolytic activity 
of C4A compared with C4B reflects the four- to fivefold differ- 
ence in binding of C4A to the antibody-coated red cell sur- 
face (16,  17). 
Clearance of  Antigen after Primary and Secondary Immuniza- 
tion.  C4Def g.p.'s were injected intravenously with a mix- 
ture of 2  x  109 PFU of bacteriophage ~X  174/kg and ei- 
ther 2.5 mg of human C4A,  C4B,  or 3  ml of normal g.p. 
serum. As controls, C4Def and strain 13 g.p. were administered 
antigen only (see diagram in Fig. 2). The presence of active 
C4  and bacteriophage in the circulation after the injection 
Dey 0: Injections  2 X 10 g PFU  @X174/kg 
and 30 rain.  +  2.5 mg C4A or C48 
blood  sample  or 3ml NG.P.S  or  no  C4 
~174 
Bleeding; 
weeks I-4 
D  ay~  reinject antigen  2 X 109 PFU  eX174/kg 
~X174 
61eeding: 
weeks 5-7 
Figure 2.  Diagram  showing immunization protocol. For primary im- 
munization, C4-deficient  guinea pigs were administered antigen (2 x  109 
PFU bacteriophage  ~X174/Kg) alone or with 2.5 mg of purified human 
C4A or C4B protein or 3 ml of fresh normal g.p. serum. For secondary 
immunization, animals were given the same dose of antigen alone. 
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Figure 3.  (a) Clearance of bacteriophage  after primary immunization with bacteriophage ~X174. Note that results from reconstitution of C4-deficient 
g.p. reconstituted  with human C4A are not included in the comparison￿9 (b) Clearance of bacteriophage  after secondary immunization. Animals were 
bled within 30 min of injection of phage  and  then at  5,  24,  and 28 h. 
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Figure 4.  (a) Primary and secondary 
humoral immune response to ~bX174. 
Animals  were  injected  intravenously 
with 2  x  109 PFU/kg of body weight 
and with or without C4 (see inset for 
treatment) at day 0. Secondary immu- 
nization was administered with antigen 
only at week 4. Animals were bled at 
1-wk  intervals  through  week 8,  and 
total  antibody  titer  was  determined 
using the plaque  neutralization  assay. 
(b) Secondary (IgG) immune response 
to  ~X174.  Animals  were  treated  as 
above, except sara from weeks 4-7 were 
treated with 0.1 mM mercaptoethanol 
overnight before neutralization  assay. 
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about two logs less than that of those treated with C4B. At 
5 h postinjection, the level of phage was <10 PFU/ml in C4A, 
whereas  the  C4B  had  a  titer  of ~104  PFU/ml.  Thus,  a 
significant difference in antigen clearance was observed after 
the  secondary challenge with  antigen. 
Primary and Secondary Humoral Immune Responsg  Animals 
were bled each week after the primary and secondary immu- 
Table  1.  Primary  and Secondary Humoral Immune Response 
Primary response*  Secondary response* 
Guinea pig  (week  1)  (week  5) 
p  value s 
Standard error*  C4A vs.  C4B 
week  1 week 5  week  1  week  5 
C4Def g.p. 
173  40  100 
168  100  200 
169  100  100 
121  10  40 
112  10  200 
113  10  10 
Mean  45  180 
C4Def g.p.+ C4A 
119  400  1,000 
171  500  1,000 
143  200  ND 
144  200  2,000 
Mean  325  1,333 
C4Def g.p.  +  C4B 
153  50  200 
154  50  ND 
126  100  200 
128  50  100 
Mean  62  167 
C4Def g.p.  +  n.g.p.s. 
151  200  400 
152  200  ND 
170  400  200 
163  400  6,000 
164  400  200 
Mean  320  1,700 
Normal g.p. 
125  200  2,000 
115  800  5,000 
172  800  10,000 
18  33 
75  340  p  <  0.02 p  <  0.03 
12.5  33.5 
50  1,430 
Mean  600  5,667  200  2,350 
" Antibody titer is the reciprocal of serum dilution resulting in 50% neutralization of phage. 
* SEM of titer at weeks I  and 5. 
$ Comparison of the standard errors of C4A and C4B using student's t test. 
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Figure 5.  Modal of binding of 
nascent C4b to antigen  in the pri- 
mary immune response after ac- 
tiv3tion by C1. Ef~dency of cova- 
lent binding  of C4b is determined 
by steric and dectrostatic interac- 
tions between the polymorphic re- 
gion of C4 and the antigen. 
nization, and their serum was assayed for specific antibody 
using a phage neutralization  assay (titer =  reciprocal of the 
serum dilution resulting in 50% neutralization).  As shown 
in Fig. 4 a and Table 1, a significant (p <  0.02) difference 
was observed in the primary immune response of the C4A 
and C4B g.p.'s. C4Def g.p:s reconstituted with either C4A 
or normal g.p. serum gave a greater response than did those 
reconstituted with C4B or those untreated. By the second 
week, the titer of all C4Def g.p:s dropped to background; 
whereas the titer of strain  13 g.p:s was still detectable and 
increased slightly over the next 2 wk. A dramatically different 
pattern was observed after the second injection  at week 5. 
The mean titer of the C4A (1,333  -+ 340 SEM) was about 
eightfold greater than that of C4B (167 _+ 33.5 SEM), which 
was significant (p <  0.03).  Over the next 2 wk the mean 
titer of C4B had dropped to near background; whereas the 
mean titer of C4A was "~800. As reported by others, recon- 
stitution of C4Def g.p's with normal g.p. serum also restored 
their immune response (see Table 1). 
To confirm that the apparent secondary response of C4A 
animals was a memory response, i.e., switch from IgM to 
IgG,  aliquots of serum were treated with 2-ME before the 
phage neutralization  assay. The IgM but not the IgG frac- 
tion of specific antibody should be sensitive to the treatment 
and no longer neutralize the phage (19). Although the mean 
titer of the reconstituted g.p:s was lower, the pattern observed 
was similar to the untreated sera (Fig. 4 b). At week 5, the 
mean titer of C4A-reconstituted  g.p's was about eightfold 
greater than those reconstituted with C4B, and it dropped 
only slightly over the next 2 wk as is characteristic of a sec- 
ondary response. For the same time period, the mean titer 
of C4B animals dropped to background as seen in the pri- 
mary immune response. As expected, the C4Def g.p:s recon- 
stituted with normal g.p. serum also switched from IgM to 
IgG; whereas the untreated C4Def g.p.'s failed to secrete a 
detectable level of IgG. 
Discussion 
Assays in vitro had shown that the two isotypes of human 
C4 protein differed dramatically in binding to hydroxyl (car- 
bohydrate) and amino groups (protein)  (16, 17). However, 
it was not clear if this difference would affect the role of C4 
in the immune response in vivo. To address this question, 
C4Def g.p.'s were reconstituted with either human C4A or 
C4B, and their humoral immune response to bacteriophage 
antigen was examined. 
Comparison of animals reconstituted transiently with ei- 
ther C4A or C4B showed a dramatic difference in both their 
clearance of antigen and their humoral immune response after 
the secondary challenge with antigen. The C4A-reconstituted 
animals not only cleared the phage antigen quicker, they also 
produced a memory response, whereas C4B-reconstituted 
animals did not. The most probable explanation for the differ- 
ence in secondary response is that reconstitution with C4A 
resulted in a more efficient activation of B lymphoeytes in 
the primary immune response. It seems  unlikely that enhance- 
ment of the immune response was due to a differential inter- 
action between the isotypes and the g.p. immune system; 
because the C4A and C4B proteins  decay at a similar rate 
in the C4Def g.p's (Fig. 1) and they interact similarly with 
g.p. components of classical pathway as demonstrated by the 
reconstitution of C4Def g.p. serum. 
In light of the selective difference in binding between the 
two C4 isotypes, the phage capsid surface would provide a 
more suitable acceptor surface for C4A than C4B. Its icosa- 
hedral capsid is thought to be assembled from repeating units 
of the F protein (48 kD) and three smaller spike proteins, 
and it does not appear to bear carbohydrate (23). The dia- 
gram in Fig. 5 provides a model illustrating  the putative in- 
teraction of  nascent C4b (activated C4) with antigen and nat- 
ural antibody (IgM) in a primary immune response. In this 
model, binding of nascent C4b to antigen depends on steric 
and electrostatic interactions between the C4 polymorphic 
region and the antigen (18). AUotypic variation, which occurs 
in the same region (11, 12), may also be important in the 
binding reaction. 
It is interesting that after the secondary challenge the strain 
13 animals cleared the antigen to near background within 
30 min (earliest time point) (Fig. 3 b). The pronounced differ- 
ence in clearance  between the strain 13 and C4A-reconstituted 
g.p's reflects, in addition to a difference in phage-antibody 
titer, the importance of immune adherence (24, 25), which 
is mediated by the classical pathway. In the transiently recon- 
stituted animals, clearance was probably mediated by anti- 
body and cells bearing Fc receptors since the human C4 was 
no longer active at week 4. However, a role for the alterna- 
tive pathway of complement, which is intact and can be acti- 
vated by immune complexes (26), could not be ruled out. 
Since the clearance of  phage was based on a biological plaque 
assay, it is possible that circulating phage were present in the 
test serum but were not active. However, this possibility seems 
unlikely at least in the C4Def g.p's in light of the low titer 
of antiphage antibody measured before the secondary chal- 
lenge with antigen. The finding that the ratio of IgG to IgM 
was much lower in the C4A animals than strain 13 also sug- 
gests the importance of an intact classical  pathway for a normal 
memory  response. As observed by others (19, 22), the C4Def 
541  Hnco et al. g.p's reconstituted with normal  g.p.  serum also developed 
a secondary response. 
Individuals homozygous for deficiency in C4A or C4B are 
more at risk to certain diseases  than those expressing both 
isotypes (27). For example, susceptibility to infection with 
encapsulated bacteria segregates with homozygous deficiency 
in C4B rather than with C4A (28, 29). However, homozy- 
gous deficiency in C4A is a major risk factor for systemic 
lupus erythematosus (30, 31). According to the hypothesis 
of Porter (13), these associations reflect the distinct binding 
preferences of the two isotypes. The functional difference found 
in this study provides the first support in vivo for this hy- 
pothesis. 
Rescue of the memory response in C4Def g.p.'s by tran- 
sient reconstitution with human C4A protein emphasizes the 
importance of an intact classical pathway in the early stages 
of a primary immune response. Attachment of the C3b/C4b 
ligands to complexes of natural antibody and antigen in the 
first 48 h of the primary response appears to be critical for 
efficient immune clearance and priming of the B cell memory 
response (32-35),  although this effect can be overridden by 
using nonphysiologic doses of antigen or adjuvant (19, 22). 
It will be important  to extend these studies with different 
variants  of C4  and chemically different antigens. 
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